Literature DB >> 29450343

Conjunctival autograft in pterygium treatment.

Sorin Simion Macarie1, Daniela Mariana Macarie2.   

Abstract

Pterygium is characterized by the thickening of the bulbar conjunctiva and the invasion of the cornea from the sclerocorneal limbus to the central portion of the cornea. Pterygium produces corneal deformation, which extends toward the central portion of the cornea. The visual disorders depend on the corneal extent. The treatment goal is the removal of the corneal and conjunctival portion of the pterygium and the coverage of the resulting conjunctival defect. The association of the pterygium surgical excision was assessed with conjunctival autograft. For this purpose, a retrospective study was performed on 68 patients and was extended over 7 years (2009-2015). Patients with recurrent pterygium were excluded. The time for corneal re-epithelization and for the pain and photophobia disappearance was followed. The incidence of recurrence was also observed. Pain levels were assessed by using a 10-point visual analog linear scale (VAS). The mean time for ocular pain and photophobia disappearance was of 48 hours. The mean pain score was 3.38 at 24 hours after surgery. Corneal re-epithelialization was achieved in 60 hours after surgery. Recurrence occurred in 6 patients. It was concluded that pterygium surgical excision with conjunctival autograft is effective in pterygium surgery.

Entities:  

Keywords:  conjunctival autograft; pterygium; pterygium management; pterygium recurrence

Mesh:

Year:  2016        PMID: 29450343      PMCID: PMC5720130     

Source DB:  PubMed          Journal:  Rom J Ophthalmol        ISSN: 2457-4325


  16 in total

1.  Observation of long-term efficacy of corneal limbal conjunctival autografts in microscopy treatments of pterygium.

Authors:  Yangfan Yang; Minshi Pi; Fasong Xu
Journal:  Eye Sci       Date:  2013-06

2.  Pterygium recurrence, astigmatism and visual acuity following bare-sclera excision and conjunctival autograft with or without additional phototherapeutic keratectomy.

Authors:  Julia Promesberger; Sharmila Kohli; Holger Busse; Constantin E Uhlig
Journal:  Ophthalmic Res       Date:  2013-11-20       Impact factor: 2.892

3.  Comparison of conjunctival autografts, amniotic membrane grafts, and primary closure for pterygium excision.

Authors:  P Prabhasawat; K Barton; G Burkett; S C Tseng
Journal:  Ophthalmology       Date:  1997-06       Impact factor: 12.079

4.  Concomitant examination of inflammation and angiogenesis in the pathogenesis of primary moderate pterygium in a well-designed case-control study.

Authors:  Shahla Talghini; Abdollah Shenasi
Journal:  Pak J Biol Sci       Date:  2013-10-01

5.  Evaluation of the recurrence rate for pterygium treated with conjunctival autograft.

Authors:  O Kocamis; M Bilgec
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-09       Impact factor: 3.117

6.  Conjunctival autograft in primary and recurrent pterygium: a study.

Authors:  Kavita Mallikarjun Salagar; Kalyanappa Gurlingappa Biradar
Journal:  J Clin Diagn Res       Date:  2013-12-15

7.  Risk factors for pterygium recurrence after surgical excision with combined conjunctival autograft (CAG) and intraoperative antimetabolite use.

Authors:  B A Olusanya; O A Ogun; C O Bekibele; A O Ashaye; A M Baiyeroju; O Fasina; A O Ogundipe; A O Ibrahim
Journal:  Afr J Med Med Sci       Date:  2014-03

8.  Amniotic membrane graft for primary pterygium: comparison with conjunctival autograft and topical mitomycin C treatment.

Authors:  D H Ma; L C See; S B Liau; R J Tsai
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

9.  [Mitomycin C related complications shouldn't be neglected in the pterygium surgery].

Authors:  Wei-yun Shi; Fu-hua Wang
Journal:  Zhonghua Yan Ke Za Zhi       Date:  2013-10

10.  Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.

Authors:  Mohammad-Reza Razeghinejad; Mohammad Banifatemi
Journal:  J Ophthalmic Vis Res       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.